Loading
companiesCompany
Actuate Therapeutics
A Texas biotech developing elraglusib, a GSK-3 beta inhibitor that improved survival in a randomised phase 2 in metastatic pancreatic cancer.
Overview
Actuate Therapeutics listed on Nasdaq in 2024 to fund elraglusib. Its lead programme is first-line metastatic pancreatic cancer with gemcitabine and nab-paclitaxel, where the Actuate 1801 Part 3B randomised phase 2 reported longer survival; the company is planning a confirmatory phase 3 and also studies the drug in Ewing sarcoma and other tumours.
Headquarters
Fort Worth, Texas, United States, US
Scorecard
All companies#456of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2015
Phase 2Small-molecule GSK-3 beta inhibitor
Elraglusib blocks a kinase that helps pancreatic cancer resist chemotherapy; in a randomised phase 2 it lengthened survival when added to gemcitabine and nab-paclitaxel, and a phase 3 is planned.